SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

KURA

Kura Oncology, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor for follow-up trial updates, potential trial expansion or fast-track designation, and any signs of partnership interest, as these data may position darlifarnib as a meaningful combination therapy in refractory RCC. The stock may react positively to further de-risking of the program.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.68
T+0 close · Apr 17, 2026 · via day close
Latest settled
+16.12%
T+60 · $11.24
Vs SPY
+9.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $9.68entry
  2. T+1 · 7mo ago +1.03%α +1.22% · $9.78
  3. T+5 · 7mo ago −4.34%α −4.89% · $9.26
  4. T+20 · 6mo ago +0.62%α −4.75% · $9.74
  5. T+60 · 4mo ago +16.12%α +9.97% · $11.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology announced preliminary clinical data from a subset of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib, showing a 44% objective response rate and 94% disease control rate with its investigational combination of darlifarnib and cabozantinib. The results suggest potential to overcome resistance to VEGF TKI therapy in a heavily pretreated population, with durable responses observed and a manageable safety profile. The data were presented at IKCS: Europe and discussed in a virtual investor event.

Key Facts

  • Preliminary data from 16 ccRCC patients previously treated with cabozantinib showed a 44% objective response rate (ORR) and 94% disease control rate (DCR).
  • Tumor shrinkage occurred in 75% of patients, with reductions ranging from 32% to 47% among responders.
  • Treatment durations ranged up to 56 weeks, with one-third of patients still on therapy at data cutoff.
  • Darlifarnib is being evaluated in combination with cabozantinib in the ongoing FIT-001 trial, with dose expansion underway.
  • Virtual investor event held on April 17, 2026, to discuss findings.

Financial Impact

No direct financial figures disclosed, but strong clinical data may enhance valuation and partnership potential.

market sentimentclinical pipeline valueinvestor confidence

Risk Factors

  • Data are preliminary and from a small subset (n=16), with limited statistical power.
  • Future clinical trials may not replicate these results, and regulatory approval is not guaranteed.
  • Competition in the RCC space is intense, with multiple existing and emerging therapies.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276007

Track record

29 reports on KURA

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026